CureVac(CVAC) - 2022 Q4 - Earnings Call Presentation

$Capital raise of $250 million in Feb 2023 Validated mRNA Platform Corporate Development Growing the talent base: >1,100 employees New sites State-of-the-art technologies Financial Execution CureVac Pipeline: A Diversified Portfolio Manufacturing ▪ The RNA Printer: Obtain first manufacturing licenses for drug substance oncology constructs H2 CureVac │ Fourth Quarter and Full-Year 2022 Results | 8 Flu SV mRNA: modified monovalent ▪ Licensed comparator vaccine CV0501: modified monovalent ▪ Fully enrolled with ...